- Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
- Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
- European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
- Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk
- FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Wechsel in der erweiterten Konzernleitung von Roche
- Changes to the Roche Enlarged Corporate Executive Committee
- Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
- FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.40 |
---|---|
High | 32.70 |
Low | 32.40 |
Bid | 32.70 |
Offer | 33.40 |
Previous close | 32.50 |
Average volume | 772.11 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 17.30 |
Market cap | 228.98bn USD |
EPS (TTM) | 2.02 USD |
Data delayed at least 15 minutes, as of Jun 20 2024 11:31 BST.
More ▼